Journal of Hematology Oncology Pharmacy

Featured Articles

Pegaspargase-Induced Diabetic Ketoacidosis in a Patient with Acute Lymphoblastic Leukemia

Ellen Madarang, PharmD, BCOP, Leslie Gallardo, PharmD, BCPS, Terrence Bradley, MD

How I Treat Anemia Associated with Lower-Risk Myelodysplastic Syndromes

Brenna Rowen, PharmD, BCOP

Pharmacy Resident–Led Medication Reconciliation and Patient Education Service in Adults with Leukemia Receiving Anticancer Oral Agents: A Pilot Study

Lily Y. Jia, PharmD, BCOP, Jessie Signorelli, PharmD, BCOP, Samantha O. Luk, PharmD, BCOP, E. Bridget Kim, PharmD, BCPS, BCOP, Gayle C. Blouin, PharmD, BCOP

Immune-Related Adverse Events Linked to Immune Checkpoint Inhibitors: Retrospective Analysis of a Single-Center Veteran Population

Jessica M. Tran, PharmD, BCPS, Ni-Chi Wu, PharmD, BCOP, BCPS, Rajkumar J. Sevak, PhD, RPh, Pankaj Gupta, MD, FACP

Denosumab for First-Line Treatment of Hypercalcemia Associated with Malignancy: Retrospective Analysis

Katherine P. Morgan, PharmD, BCOP, CPP, Yujiao Sun, PharmD, Allison Deal, Jared Weiss, MD, Amber Cipriani, PharmD, BCOP

From the Literature

Daily Aspirin Does Not Lower Colorectal Cancer Risk When Started After Age 70

Adjuvant Nivolumab Therapy Prolongs Disease-Free Survival in Patients with Esophageal Cancer

New Data Reveal Mismatched Need and Supply of Oncology Physicians and Pharmacists in America

FDA Updates

FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial

Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation

Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations

Meeting Highlights

Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma

Two Ways to Target Tumors with KRAS Mutations

Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations

Ceritinib Effective in Treating Brain Metastases in NSCLC

Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.